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INTRODUCTION 
INTRODUCTION 
 
Eclampsia (Greek – Shining Forth) 
 An acute and life threatening complication of pregnancy is 
characterized by the appearance of tonic clonic seizures, in a patient with 
pre-eclampsia.1 
 It is estimated to complicate 1in 2000 deliveries in developed 
countries and from 1 in 100 to 1 in 1,700 deliveries in developing 
countries.2 
Eclampsia accounts for 50,000 maternal deaths a year world 
wide.The maternal case fatality rate is 1.8% and 35% of eclamptics will 
have one major complication.3 The perinatal mortality rate in developing 
countries is as high as 80 (or) more per 1000 births. 
 Although it is a standard practice to use anticonvulsants for 
management of Eclampsia, the choice of agent is controversial.4 
Magnesium sulphate was first used in the treatment of puerperal 
eclampsia in 1925. 
 Pritchard5 (1955) published his initial experience with magnesium 
sulphate in the treatment of eclampsia. The first two randomized trials of 
anticonvulsant treatment in eclampsia were published in 1990.  
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 The Collaborative Eclampsia Trial (CET)  involving 1687 women 
with eclampsia in the year 1995 provides compelling evidence that 
magnesium sulphate reduces the risk of recurrent seizures as compared 
with diazepam and phenytoin and also less maternal and neonatal 
morbidity than the other agents.6 
 A prospective study included 65 eclamptic patients receiving lower 
dose of magnesium sulphate therapy at Dhaka Medical College Hospital 
from 25th  March 1998 to 15th  June 1998.7 
 The loading dose of Dhaka regimen was significantly less than that 
used by CET and Pritchard regimen – 10gm loading dose as compared to 
14gm and the maintenance dose was 2.5gm intramuscularly 4th hourly 
which was half of the maintenance dose used in Pritchard regimen. With 
this regimen, the maternal mortality rate in Dhaka medical college has 
fallen dramatically. 
 The present study compares the Pritchard regimen with the Dhaka 
regimen of magnesium sulphate in the management of Antepartum 
eclampsia and compares the maternal and perinatal out come in the 
patients treated with the two regimens. 
 
 
 
 
 
 
 
AIM OF STUDY 
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AIM OF THE STUDY 
 
 
 Magnesium sulphate has been shown to be the drug of choice for 
the control of seizures in eclampsia. However, its toxicity, which is linked 
to serum magnesium level, can be life-threatening for the mother and 
affects the neonatal outcome. Hence, the aim of the present study is  
Ø To study the safety and efficacy of low-dose magnesium sulphate 
regimen – Dhaka regimen in the treatment of Antepartum 
Eclampsia. 
Ø To compare the effects of Dhaka regimen with the Pritchard 
regimen. 
 a) The efficacy of controlling convulsions in Antepartum 
 Eclampsia.  
  b) In preventing the recurrence of convulsions. 
Ø To compare the maternal and perinatal outcome with the two        
regimens – Dhaka regimen and the Pritchard regimen. 
 
 
 
 
REVIEW OF 
LITERATURE 
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REVIEW OF LITERATURE 
 
Definition 
 Preeclampsia complicated by generalized tonic-clonic convulsions 
is termed Eclampsia. Fatal coma without convulsions also is called 
eclampsia. However, it is better to limit the diagnosis to woman with 
convulsions and to regard deaths in non convulsions cases as due to 
severe preeclampsia.8 
 Depending on whether convulsions appear before, during (or) after 
labour, eclampsia is designated as Antepartum, Intrapartum (or) Post 
partum eclampsia. 
 
Etiology 
 The exact etiology of pre eclampsia still remains unknown. Several 
theories have been proposed. Since eclampsia is a severe form of 
preeclampsia, the histopathological and biochemical changes are similar 
although intensified when compared to those of preeclampsia.9  
 According to Sibai10 (19), currently plausible potential causes 
include the following, 
(i)  Abnormal trophoblastic invasion of uterine vessels.  
(ii) Immunological intolerance between maternal and fetoplacental 
 tissues. 
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(iii) Maternal maladaptation to cardiovascular or inflammatory  
           changes of normal pregnancy. 
(iv) Dietary deficiencies  
(v) Genetic influences  
 
Table -1 Risk factors for pre-eclampsia11 
 
 Relative risk (RR) 95% Cl 
Genetic factors 
 Genetic pre-disposition 
 Race and ethnicity: more common in 
 Blacks and Asians. 
 Family history of pre-eclampsia 
 Pregnancy by ovum donation 
 
 
 
2.90 
 
 
 
1.70-4.93 
Age and parity 
 Teenage pregnancy 
 Age more than 40 years 
 Long interval between pregnancies 
 Nulliparity 
 
 
1.96 
 
2.91 
 
 
1.34-2.87 
 
1.28-6.61 
Partner-related factors 
 Change of partner 
 Partner who fathered a pre-eclamptic 
 pregnancy in another woman 
 Limited sperm exposure 
 Pregnancy due to donor insemination 
  
Presence of underlying disorders 
 Chronic hypertension 
 Diabetes mellitus 
 
 
3.56 
 
 
2.54-4.99 
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 Renal disease 
 Obesity (body mass index > 35 kg/m2) 
(i) Before pregnancy 
(ii) At booking 
 Maternal low birth weight 
 Polycystic ovarian syndrome 
 Migraine 
 Collagen vascular disorders 
 Uncontrolled hyperthyroidism 
 Factor V Leiden deficiency, activated 
 protein-C deficiency and thrombophilia 
 Sickle cell disease or trait and other 
 haemoglobinopathies 
 Anti-phospholipid antibodies 
 Protein-S deficiency and 
 hyperhomocysteinaemia  
 
 
2.47 
1.55 
 
 
 
 
 
 
 
 
 
9.72 
 
 
1.66-3.67 
1.28-1.88 
 
 
 
 
 
 
 
 
 
4.34-21.75 
Pregnancy-related risk factors 
 Multiple pregnancy 
 Hydatidiform mole 
 Hydrops fetalis 
 Congenital and chromosomal fetal 
 anomalies (trisomy 13, triploidy) 
 Urinary tract infection 
 
2.93 
 
2.04-4.21 
Miscellaneous factors 
 Smoking (reduced risk) 
 Psychological strain and stress at 
 working  place 
 Previous history of pre-eclampsia 
 Raised blood pressure (diastolic>80 
 mmHg) at booking 
 
 
 
 
7.19 
1.38 
 
 
 
 
5.85-8.83 
1.01-1.87 
Cl = Confidence interval   
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Genesis of preeclampsia as a two-stage disorder12 
Maternal factors Placental factors
1. Genetic
2. Underlying medical disorders
    (thrombophilias, diabetes,
hypterhomocysteinaemia, obesity,
    chronic hyptertension, etc.)
3. Immune-maladaptation to
    pregnancy
1. Shallow trophoblast invasion in
    spiral arteries (abnormal
placentation)
2. Placental ischaemia
    (hypoperfusion)
Stage-1
Balance tilted in
fvaour of oxidative
stress markers
Connecting
link
Oxidative stress
Free radicals (oxidative
stress markers; increased)
Antoxidants
(decreased)
Endolthelial dysfunction
Stage 2
Pre-eclampsia
Good endothelium Bad endothelium
Mild disease Severe disease
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PATHOGENESIS 
1) Vasospasm 
 The concept of vasospasm was documented by Volhard (1918) 
based on direct observation of small vessels in nail beds, ocular fundi and 
bulbar conjunctiva. Wang and colleagues13 (2002) demonstrated 
disruption of endothelial junctional proteins. Suzuki et al.,14 (2003) 
demonstrated the ultra structural changes in sub endothelial region of 
resistance arteries in preeclamptic woman. With diminished blood flow, 
ischaemia of the surrounding tissues would lead to necrosis, haemorrhage 
and other end-organ disturbances as characteristic of the syndrome.  
Vasospasm may be worse in HELLP syndrome (Fisher et al., 2000)15.  
 
2) Endothelial cell activation 
Hayman et al.16 (2000) showed that clinical syndrome of 
preeclampsia results from widespread endothelial cell changes.  
 
(3) Increased Pressor responses 
 Abdul – Karim and Assali17 (1966) showed that normal pregnant 
women develop refractoriness to infused vasopressors. Women with early 
preeclampsia have increased vascular reactivity to infused nor 
epinephrine and angiotensin II. (Raab et al., 1956 and Talledo et al., 
1968).18 
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(4) Prostaglandins 
 Taylor and Roberts19 (1999) showed that endothelial prostacyclin 
production mediated by phospholipase A2 is decreased in preeclampsia. 
Thromboxane A2 secretion by the platelets is increased and the 
prostacyclin: thromboxane A2 ratio decreases. This favours increased 
sensitivity to angiotensin II that ends in vasoconstriction. 
 Chavarria20 (2003) gave the evidence that these changes are 
apparent as early as 22weeks in woman who later develops preeclampsia. 
 
(5) Nitric Oxide 
 A potent vasodilator synthesized from L-arginine by endothelial 
cells. It is the compound that maintains the normal low-pressure 
vasodilated state characteristic of feto placental perfusion – Myat et al. 21 
(1992). 
 Wang et al. 22 (1992) showed that preeclampsia is associated with 
decreased endothelial nitric oxide synthase expression, which increases 
cell permeability. Its production is increased as a compensatory 
mechanism in severe preeclampsia.  So increased serum concentration of 
nitric oxide is likely the result of hypertension, not the cause (Morris et 
al.1996). 
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(6) Endothelins 
 Mastrogiannis and coworkers23 showed that these 21 amino acid 
peptides are potent vaso constrictors, and endothelin-1 (ET-I) is the 
primary isoform produced by human endothelium. 
 Taylor and Roberts24 (1999) showed that the placenta is not the 
source of increased ET-I  and it is likely to arise from systemic 
endothelial activation. 
 Sagsoz and Kucukozkan25 (2003) observed that the treatment of 
preeclamptic woman with magnesium sulphate lowers ET-1 
concentrations. 
 
(7) Angiogenic Factors 
 Vascular Endothelial Growth Factor (VEGF) and Placental Growth 
Factor (PlGF) are the glycosylated glycoproteins that are selectively 
mitogenic to endothelial cells.  Simmons et al. 26 (2000) showed that 
VEGF is increased in serum from woman with preeclampsia but the 
bioavailability is decreased. In preeclampsia, the gene for Soluble Fms-
Like tyrosine kinase 1 (SFLt) is up regulated – Maynard et al. 27(2003) 
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PATHOPHYSIOLOGY OF ECLAMPSIA 
 
 Loss of cerebral vascular autoregulation lead to either 
overdilatation or intense vasospasm.  As part of the autoregulatory 
response to severe hypertension, cerebral vasoconstriction occurs which 
leads to ischaemia, cytotoxic edema and infarction. When the 
autoregulatory mechanism fails at some point, dilatation of vessels occurs 
resulting in hyper perfusion and vasogenic edema.28 
 Autopsy studies showed edema, cortical and while matter 
microinfarcts, pericapillary and parenchymal bleeding and vascular 
lesions predominantly in the occipital and watershed areas.29 
 
Symptoms and signs of impending eclampsia 
1. Headache      - Persistent occipital or frontal 
2. Visual disturbance     - Blurred vision and photophobia. 
3. Restlessness and agitation 
4. Epigastric and/or right upper quadrant pain 
5. Nausea and vomiting 
6. Oliguria 
7. Laboratory evidence of disseminated intravascular coagulation. 
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Clinical Course of eclampsia 
 Eclamptic seizure as stated by Chesley30 has 4 stages. 
 
(i) Stage of invasion - The patient becomes unconscious.      
                                                  There is twitching of the muscles of the                                                    
 face, tongue and limbs which lasts for 
 about  30 seconds. 
(ii) Stage of contraction - The whole body goes into a tonic spasm.                                                
     Cyanosis appears. This lasts for about  
     30 seconds. 
(iii) Stage of convulsion - All voluntary muscles undergo alternate                                              
 contraction and relaxation. Biting of the 
 tongue occurs. This lasts for about  
 1-4 minutes.                                                 
(iv) Stage of coma  - Following the convulsions, the patient 
     passes on to the stage of coma which  
     usually lasts for a brief period. 
Differential Diagnosis 
 Epilepsy, Hysteria, Encephalitis, Meningitis, Puerperal cerebral 
thrombosis, cerebral malaria in tropics, cysticercosis, Intra cranial 
tumour.  
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Complications of Eclampsia  
Maternal complications 
(i) Maternal Injuries  
(ii) Placental Abruption (10%) 
(iii) Neurological deficits (7%) 
(iv) Aspiration pneumonia (7%) 
(v) Pulmonary edema (5%) 
(vi) Disseminated intra vascular coagulation (3%) 
(vii) Cardio pulmonary arrest (4%) 
(viii) HELLP syndrome (4%) 
(ix) Acute Renal failure (4%) 
(x) Maternal death (1%) 
 
Fetal complications 
 The perinatal morbidity and mortality rate is very high to the extent 
of about 30 – 50%. The causes are:  
(i) IUGR due to chronic placental insufficiency. 
(ii) Prematurity – either spontaneous or induced. 
(iii) Intra uterine asphyxia  
(iv) Effects of the drugs used to control convulsions. 
(v) Increased operative deliveries.  
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MANAGEMENT 
 
I. General Management 
 It plays an important role in the management of eclampsia. The 
patient is nursed in a quiet room with a medical or nursing attendant 
always present. Pulse rate, respiration, blood pressure, oxygen saturation, 
restlessness, urine output must be constantly observed. A mouth gag, 
airway and O2 must be available. Patient is put in left lateral position in a 
railed cot. Throat is cleared of secretions and vomitus by intermittent 
suctioning.  A soft firm mouth gag introduced in time will save injury to 
the tongue. An indwelling catheter in the bladder will give an accurate 
assessment of the urine output and will also prevent restlessness due to a 
full bladder. Blood pressure is measured half hourly till it is controlled 
and then second hourly. A record of grade of consciousness is 
maintained. Nutrition and hydration are maintained parenterally. 
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II. ANTICONVULSANT LINE OF MANAGEMENT 
Dosage schedule of various regimens 
1. Menon’s Regimen (1961) 31 
Chlorpromazine  25 mg and pethidine 100 mg in 20 ml of 5% 
glucose is  given intravenously along with 50 mg of chlorpromazine and 
25 mg promethazine given intramuscularly. 
 Subsequently, promethazine 25 mg and chlorpromazine 50 mg are 
given intramuscularly alternatively at four hourly intervals for 24 hrs 
following the last fit.  
Menon (1961) used lytic cocktail in 1448 eclamptic women and 
maternal mortality rate was 2.2%.  
 
2. Diazepam 32 
 A loading dose of 10 mg diazepam intravenously over 2 minutes is 
followed by an intravenous infusion of 40 mg in 500 ml of normal saline 
for 24 hours. Rate of infusion titrated against the level of consciousness 
with the aim of keeping the woman sedated but arousable. Diazepam can 
cause respiratory depression. It is poorly excreted by the neonates and 
they tend to be sedated, hypothermic and unable to breast feed for several 
days. Maternal mortality rate using this regimen was 5%. 
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3. Magnesium Sulphate (MgSO4) 
 In 1955, Pritchard initiated a standardized treatment regimen at 
Parkland Hospital. 
 In 1964, Zuspan initiated the intravenous magnesium sulphate 
regimen. 
 
a) Pritchard Regimen 33 
Loading Dose Maintenance Dose 
4 gm of 20% MgSO4 IV at a rate 
not exceeding 1 gm/min 
Every 4 hrs  thereafter, 5gm of 50% 
MgSO4 as IM on alternate buttocks 
after ensuring 
10 gm of 50% MgSO4 as deep IM, 
5 gm in each buttock through a  
3 inch long – 20 gauge needle 
a) Patellar reflex is present 
b) Respiration rate > 16/minute 
c) Urine output > 100 ml in the  
    preceding 4 hours 
If convulsions persists after 15 
minutes, 2 gm of 20% MgSO4 IV is 
given at a rate not exceeding 1 
gm/minute 
MgSO4 is continued for 24 hours 
after delivery or the last episode of 
convulsion whichever is later. 
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b) Zuspan’s Regimen (1964)  
Loading Dose Maintenance Dose 
4 gm of 20% MgSO4 IV at a rate 
not exceeding 1 gm /min 
1 – 2 gm/hour by controlled 
infusion pump for 24 hours after 
delivery (concentration not to 
exceed 20%) 
 
c) Dhaka Regimen7 (1998)  
Loading Dose Maintenance Dose 
4 gm of 20% MgSO4 IV at a rate 
not exceeding 1 gm/min 
Every 4 hrs  thereafter, 2.5gm of 
50% MgSO4 as IM on alternate 
buttocks after ensuring 
6 gm of 50% MgSO4 as deep IM,  
3 gm in each buttock through a 3 
inch long – 20 gauge needle 
a) Patellar reflex is present 
b) Respiration rate > 16/minute 
c) Urine output > 100 ml in the  
    preceding 4 hours 
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Phenytoin Regimen 
 It is given by slow intravenous route. Initial doses 10mg / kg body 
weight followed by 5mg / kg 2hours later. Thereafter 200mg of phenytoin 
is given orally after 12 hours. It is continued until 48 hours after delivery. 
Important side effects are hypotension, cardiac arrythmias and phlebitis at 
the administration site. Experience with phenytoin is limited.  
 
Pharmacokinetics of Magnesium Sulphate 34 
 Magnesium sulphate USP is MgSO4.7H2O. It has a molecular 
weight of 24.3.  1gm of magnesium sulphate has 98mg of elemental 
magnesium. 
 
Distribution and plasma levels 
 After administration, about 40% of plasma magnesium is protein 
bound. The unbound magnesium ion diffuses into the extravascular – 
extracellular  space, into bone and across the placenta and fetal membrane 
and into the fetus and amniotic fluid. In pregnant women, apparent 
volumes of distribution usually reach constant values between the third 
and fourth hour after administration. The pharmacokinetic profile of 
MgSO4 after intravenous administration can be described by a 2-
compartment model with a rapid distribution (a) phase followed by a 
relative slow beta phase of elimination. 
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Excretion 
 Magnesium is excreted almost solely by the kidneys.  50% of the 
infused dose is excreted after 4 hours in urine.  90% of the bolus 
intravenous dose is excreted within 24 hours. 
 
Mechanism of action 
 Some believe its action to be mainly peripheral at the neuro 
muscular junction with minimal central effects. While some believe that 
the main action is central.  Calcium entry into the neurons is regulated by 
specific excitatory amino acid linked channels. Excitatory amino acids 
such as L-glutamate and L-aspartate are the major neuro transmitters in 
mammalian central nervous system.  These neurotransmitters produce 
their effects by interacting with certain receptors on the cell surface. The 
excitatory amino acid receptor, N-methyl D-aspartate (NMDA) is the best 
characterized excitatory amino acid receptor sub type. NMDA receptor 
has its channel blocked by magnesium ion and thus blocking neuronal 
calcium influx35.  Thus magnesium has a central nervous system effect in 
blocking the seizure.  Cotton et al. 36 (1992) have shown that hippocampal 
seizures could be blocked by magnesium. 
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 Magnesium sulphate is a potent vasodilator especially in cerebral 
vasculature thus relieving cerebral vasospasm which is thought to be a 
cause for eclampsia. 
 
Other actions 
Ø Vasodilatation in vascular beds 
Ø Increased uterine blood flow  
Ø Increased renal blood flow 
Ø Increased prostacyclin release by endothelial cells  
Ø Decreased plasma renin activity 
Ø Decreased angiotensin converting enzyme levels 
Ø Attenuation of vascular response to pressor substances 
Ø Bronchodilatation 
Ø Reduced platelet aggregation 
 
Pharmacological effects 
Ø Anti convulsant action 
Ø Transient hypotensive effect 
Ø Transient but mild decrease in frequency of uterine contractions 
but no change in the intensity of contractions 
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Ø Clinically insignificant decrease in short term variability of fetal 
heart rate 
Ø No change in long term variability of fetal heart rate or fetal heart 
rate accelerations 
 
Side effects 
 First sign of magnesium toxicity is usually the loss of patellar 
reflex that occurs usually at about 9-12mg/dl because of curariform 
action.  So maintenance dose of MgSO4 is not to be given in the absence 
of patellar reflex. 
 Early signs and symptoms of magnesium toxicity include nausea, 
feeling of warmth, flushing, somnolence, double vision, slurred speech 
and weakness.  These symptoms usually develop at plasma levels of 9 to 
12 mg/dl. Muscle paralysis and respiratory arrest develop at plasma level 
of 15-17mg/dl.  Hence respiratory rate is monitored closely. 
 Cardiac arrest develops at a level of 30-35 mg/dl.  Thus, it is 
important to keep an ampoule containing 1 gram of calcium gluconate at 
the bedside for intravenous administration as an antidote in case of 
magnesium toxicity. 
 Endo - tracheal intubation and mechanical ventilation is done for 
severe respiratory depression (or) arrest.  There is a transient decrease in 
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uterine activity during intravenous injection alone.  It can cause a 
transient decrease in fetal heart rate variability, neonatal neuro muscular 
and respiratory depression, hyporeflexia and low APGAR scores.  These 
effects were reported in preterm infants in association with fetal growth 
restriction, but no ill effects in term infants.    
 
Efficacy and safety 
 Magnesium sulphate is rapidly effective, reliable and with  
predictable duration of action, wide safety margin, non depressive and 
non toxic to the mother and baby, simple to administer and monitor in the 
clinical setting and with a readily available antidote. Serum magnesium 
can be measured to ensure therapeutic concentration but many 
practitioners are happy to omit biochemical monitoring because of its 
wide margin of safety. 
 Duley et al.37 (1995) in his study used clinical evaluation alone and 
showed that the there is no need to check serum magnesium levels.  
Estimation of magnesium levels is useful in the management of treatment 
failures. 
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Drug interactions with Magnesium Sulphate 
 
Agent  Effect Recommendation 
Depolarising/non 
depolarizing neuro 
muscular blockers. 
Increased activity of 
these agents. 
May need dosage reduction 
of neuro muscular blocking 
agents.  
CNS depressants -
opioids, barbiturates, 
general anaesthetics 
Additive CNS 
depression 
May require dose reduction 
of CNS depressants 
Nifedipine Hypotension Administer with caution 
and adjust nifedipine 
dosage if necessary 
 
 
 At the neuromuscular junction, magnesium decreases the 
presynaptic release of acetylcholine and reduces the sensitivity of the post 
junctional membrane (motor end plate).  Ghoneim and Long reported that 
the actions of succinylcholine (non depolarizing agent) are potentiated by 
magnesium sulphate.  A single dose of succinylcholine can be safely used 
to facilitate tracheal intubation but may not apply when repeated doses of 
succinyl choline are used. 
 When a patient is simultaneously exposed to magnesium sulphate 
and nifedipine, some interaction might be expected as both are calcium 
channel blockers.  Women on nifedipine who are receiving magnesium 
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sulphate had effective blood pressure control without undesirable side 
effects and no cases of hypotension.  It would appear that while a 
theoretical risk of interaction could exist, in practice this is relatively 
uncommon. 
 
Anti-hypertensive agents used in pregnancy 38 
Class Drug Initiating dose 
Max 
dose Common side effects 
Centrally 
Acting Methyldopa 250mg tds 2g 
Postural hypotension, 
drowsiness, dryness of 
mouth, headache, 
depression.  
Calcium 
channel 
blockers 
Nifedipine 10mg tds  120mg 
Headache, dizziness, 
fatigue, flushing, 
palpitations heart 
burn, constipation, 
peripheral edema. 
b adrenergic 
blockers 
Labetolol  
(a & b)  
Atenolol 
100mg bd 
50mg od 
2400mg 
200mg 
dizziness, drowsiness, 
fatigue, bradycardia 
depression 
Vasodilator Hydralazine 25mg tds 300mg Flushing, headache, vomiting, diarrhoea 
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III. OBSTETRIC MANAGEMENT39, 40 
 The definitive treatment of eclampsia is delivery. Attempts to 
prolong pregnancy in order to improve fetal maturity are unlikely to be of 
value. Once seizures are controlled, severe hypertension treated, and 
hypoxia corrected, delivery can be expedited. Vaginal delivery should be 
considered but cesarean section is likely to be required in primigravidae 
remote from term with an unfavourable cervix. Vaginal prostaglandins 
increase the success of induction and augmentation of labour. 
Hypertension monitoring and control should be continued vigilantly 
throughout labour.    
 
Cesarean section is done for the following indications: 
1. All deeply unconscious patients (unless delivery is imminent) 
2. All un co-operative patients due to restlessness. 
3. If vaginal delivery is unlikely to occur with in 6-8 hr of the onset of 
first eclamptic seizure. 
4. There is an obstetric indication for a cesarean section. 
5. Fetal distress. 
  
Principles of Vaginal Delivery 42 
 Second stage of labour should be short and elective operative 
vaginal delivery can be considered. The third stage of labour should be 
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managed by either of the following so as to prevent post partum 
hemorrhage.  
i). Oxytocin 10 units in iv drip or im 
ii). Prostaglandin F2a 125mg or 250mg im 
iii). Misoprostol 600 - 800mg per rectal. 
Methyl ergometrine is contraindicated as this would result in 
further increase in blood pressure. 
 
Post Delivery 
 After delivery, close monitoring should be continued for a 
minimum of 24 – 48 hours. Since almost 20% of the patients can have 
post partum eclampsia – it is important to be vigilant and continue 
treatment for first 24 – 48 hours. Anti hypertensive treatment can then be 
gradually tapered off. 
 
 
 
 
MATERIALS AND 
METHODS 
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MATERIALS & METHODS 
 
This study was conducted in Annal Gandhi memorial Government 
Hospital, Tiruchirappalli in the department of Obstetrics and 
Gynaecology during the period of July 2008 – August 2009. 
80 consecutive patients with antepartum eclampsia were included 
in the study. Magnesium sulphate was used for the control of 
convulsions. 40 patients were put under the Pritchard regimen and other 
40 were enrolled under Dhaka regimen. 
 
Inclusion criteria  
 All patients with antepartum eclampsia irrespective of their age, 
parity and booking status.  
 
Exclusion criteria 
1. Patients having received MgSO4 before coming to hospital.   
2. Patients with preexisting seizure disorder, heart block, renal 
failure. 
3. Postpartum eclampsia with onset of convulsions >72 hrs after 
delivery.  
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Design of the study 
 Randomized control trial with randomization done using list given 
by statistician. 
 
Group A 
 40 cases of Antepartum eclampsia were randomly allocated to 
Dhaka Regimen. 
 
Group B 
 40 cases of Antepartum eclampsia were randomly allocated to 
Pritchard Regimen.  
 
History 
 A detailed history regarding age, parity, gestational age, number of 
convulsions, duration of symptoms of pregnancy induced Hypertension, 
H/0 imminent symptoms were taken from close relations and also from 
the patient if she is conscious (or) taken retrospectively from her. Any 
past history of hypertension (or) renal disease (or) eclampsia in previous 
pregnancy was elicited. 
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Clinical Examination 
 A thorough general examination and obstetric examination were 
made. On general examination, conscious level, degree of edema, 
anaemia, pulse rate, temperature, respiratory rate, blood pressure, 
cardiovascular system, respiratory system, fundus examination were 
done.  Blood and urine were sent for all investigations related to 
eclampsia like renal function tests, liver function tests, hematological 
tests and coagulation screening tests were carried out in all patients.  
A life line was established and the Regimen was started. Pulse, 
Blood pressure, Respiratory rate, Oxygen saturation monitored for every 
15 minutes, Knee jerk and urine output every half hourly. Serum 
magnesium levels measured 3 to 4 hours after the loading dose. 
 
ANTI CONVULSANT LINE OF MANAGEMENT 
1) DHAKA REGIMEN OF MAGNESIUM SULPHATE REGIMEN: 
Loading Dose 
v 4gm of 20% magnesium sulphate given intravenously slowly over 
15 minutes. 
v 3gm of 50% magnesium sulphate given intramuscularly in each 
buttock. 
 
 30 
Maintenance Dose 
v 2.5gm of 50% magnesium sulphate given intramuscularly every 4 
hours in alternate buttocks, until 24 hrs after delivery or last 
episode of fits whichever is later, provided patellar reflex is 
present, respiratory rate is more than 16/min, urine output at least 
100ml in the preceding 4 hours. 
 
2)  PRITCHARD’S MAGNESIUM SULPHATE REGIMEN 
 4gm of Magnesium sulphate (MgSO4. 7H2O, USP) as a 20% 
solution intravenously at a rate not to exceed 1gm/min, followed 
promptly with 10gm of 50% magnesium sulphate solution, 5gm deep IM 
in each buttock. 
 5gm of 50% solution of magnesium sulphate intramuscularly in 
alternate buttock every 4 hours thereafter for 24 hours after delivery or 
last fits whichever is later, provided 
a) Patellar reflex is present. 
b) Respiratory rate > 16/min 
c) Urine output in the previous 4hours exceeded 100ml. 
Anti Hypertensive Line of Management 
 Control of Hypertension is achieved by Tab.  Alphamethyl Dopa 
250mg / 500mg thrice daily and Tab. Nifidipine 10mg thrice daily. 
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Obstetric Management 
 After stabilizing the patient, a detailed obstetric examination was 
done. Mode of termination was planned according to the gestational age, 
viability of the fetus, and the cervical scoring. 
 Patients were induced with prostaglandin E2 gel and accelerated 
with Oxytocin infusion. 
 Cesarean section was done for obstetric indications (or) for failed 
induction. 
 After delivery the patient was observed carefully for 48 – 72 hours 
in the labour ward and post operative ward and followed up until the 
discharge of the patient. 
 Neonatal outcome was recorded in terms of Apgar scoring and 
birth weight. Neonates were also followed up until the discharge of the 
mother. 
 
Outcome measures 
 Primary outcome measures are recurrence of fits after starting the 
treatment in both the regimens. Perinatal morbidity and mortality and 
maternal morbidity and mortality were compared in both the groups. 
 
 
 
 
RESULTS AND 
ANALYSIS 
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RESULTS AND ANALYSIS 
 
TABLE – 1 
AGE DISTRIBUTION 
 
 
Group A 
(Dhaka regimen) 
Group B 
(Pritchard regimen) S. 
No. Age Group 
No. % No. % 
1. Below 20 06 15 01 2.5 
2. 20 – 24 18 45 19 47.50 
3. 25 – 29 15 37.50 13 32.50 
4. 30 & Above 01 2.50 07 17.50 
 Total 40 100 40 100 
 Mean 24.1625 24.3780 
 
 
Age of women in the two groups does not differ significantly.  In 
this study, 7 patients were below 20 years, 37 patients were between 20-
24 years, 28 patients were between 25-29 years and 8 patients were 30 
years and above.   The mean age for Dhaka regimen group was 24.2 years 
and mean age for Pritchard regimen group was 24.4 years which does not 
differ significantly. 
FIG. 1 
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TABLE – 2 
BOOKING STATUS 
 
Group A 
(Dhaka regimen) 
Group B 
(Pritchard regimen) S. 
No. Booking Status 
No. % No. % 
1. Booked 28 70 27 65 
2. Unbooked 12 30 13 35 
 
In the Dhaka regimen group, 28 patients were booked and 12 
patients were unbooked and in the Pritchard regimen group, 27 patients 
were booked and 13 patients were unbooked. The booking status does not 
differ significantly between the two groups. 
 
 
 
FIG. 2 
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TABLE – 3 
PARITY 
 
 
Group A  
(Dhaka Regimen) 
Group B  
(Pritchard Regimen) S. 
No. Parity 
No. % No. % 
1. Primi 27 67.50 24 60.00 
2. Multi 13 32.50 16 40.00 
 
In this study, 51 patients were pimigravidae.  In Dhaka regimen 
group, 27 patients (67.5%) were primigravidae and 13 patients were 
multigravidae and in the Pritchard regimen group, 24 patients (60%) were 
primigravidae and 16 patients were multigravidae.  Hence, the parity 
between the two groups does not differ significantly. 
 
FIG. 3 
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TABLE – 4 
GESTATIONAL AGE 
 
Group A  
(Dhaka Regimen) 
Group B  
(Pritchard 
Regimen) 
S. 
No. Gestational Age 
No. % No. % 
1. Below 24 wks. 04 10.00 00 0 
2. 25 – 28 wks. 06 15.00 02 5.0 
3. 29 – 32 wks. 09 22.50 14 35.00 
4. 33 – 36 wks. 19 47.50 19 47.50 
5. Above 36 wks. 02 5.0 05 12.50 
 Mean 32.9375 33.3953 
 P 0.310 (in significant) 
 
 
In this study, in Dhaka regimen group, 4 patients were below 24 
weeks of gestation, 6 patients were between 25 and 28 weeks, 9 patients 
were between 29 and 32 weeks, 19 patients were between 33 and 36 
weeks, 2 patients were above 36 weeks of gestational age. 
In Pritchard regimen group, none of the patients were below 24 
weeks, 2 patients were between 25 and 28 weeks, 14 patients were 
between 29 and 32 weeks, 19 patients were between 33 and 36 weeks, 5 
patients were above 36 weeks of gestational age. 
The Mean gestational age for Group A (Dhaka Regimen) is 32.94 
weeks and Group B (Pritchard regimen) is 33.40 weeks.  The P value is 
0.310, which is insignificant. 
FIG. 4 
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TABLE – 5 
NO. OF FITS BEFORE ADMISSION 
 
Group A  
Dhaka Regimen 
Group B 
Pritchard Regimen S. 
No. 
No. of Fits Before 
Admission 
No. % No. % 
1. 1 – 2 18  45.00 12  30.00 
2. 3 – 5 17  42.50 25 62.50 
3. 6 – 8 05 12.50 03 07.50 
4. Above 9 0 0 0 0 
 
Total number of fits before admission was ranged between 1 and 9 
fits.  In Dhaka regimen group 18 patients had 1 to 2 fits, 17 patients had 3 
to 5 fits, 5 patients had 6 to 8 fits and none had more than that.  
 
In Pritchard regimen group, 12 patients had 1 to 2 fits, 25 patients 
had 3 to 5 fits, 3 patients had 6 to 8 fits and none had more than that.  
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 TABLE – 6 
LEVEL OF CONSCIOUSNESS 
 
Group A  
Dhaka Regimen 
Group B  
Pritchard 
Regimen 
S. 
No. Level of Consciousness 
No. % No. % 
1. Conscious 10  25 09  22.50 
2. Semiconscious 30 75 31 77.50 
3. P Value 0.503 
 
 
 In Dhaka regimen group, 10 patients were conscious and 30 
patients were semiconscious.  In Pritchard regimen group, 9 patients were 
conscious and 31 patients were semiconscious. The level of 
consciousness of the mothers in both the groups does not differ 
significantly.  The P value is 0.503. 
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TABLE – 7 
HYPERTENSION 
 
 
Group A 
(Dhaka Regimen) 
Group B 
(Pritchard 
Regimen) 
S. 
No. 
Blood Pressure 
(mm Hg) 
No. % No. % 
 Systolic  
1. 120 – 140 02 5.00 06 15.00 
2. 140 – 160 17 42.50 15 37.50 
3. Above 160 21 52.50 19 47.50 
 Diastolic 
4. 80 – 100 13 32.50 13 32.50 
5. 100 – 110 17 42.50 13 32.50 
6. Above 110 10 25.00 14 35.00 
 
In Dhaka regimen group, two patients had systolic blood pressure 
less than 140 mm Hg and majority had more than 160 mm Hg.  In 
Pritchard regimen group, 6 patients had systolic blood pressure less than 
140 mm Hg and 19 patients had more than 160 mm Hg and the rest had 
between 140 and 160 mm Hg. 
In Dhaka regimen group, 17 patients had diastolic blood pressure 
between 100 and 110 mm Hg and 10 patients had more than 110mm Hg. 
In Pritchard regimen group, 13 patients had diastolic blood pressure 
between 100 and 110 mm Hg and 14 patients had more than 110 mm Hg. 
Hence, the blood pressure does not differ significantly between the 
two groups. 
FIG.  7A 
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TABLE – 8 
SERUM MAGNESIUM MG / DL 
 
S. 
No. Serum Magnesium 
Group A 
(Dhaka Regimen) 
Group B  
(Pritchard 
Regimen) 
1. Mean 4.0338 4.5338 
2. Standard Deviation 0.55250 0.65525 
3. P Value 0.0270 
 
 
The mean serum magnesium level in Dhaka regimen group was          
4.03 mg/dl and the mean serum magnesium level in Pritchard regimen 
group was 4.53 mg/dl.  Both were within the therapeutic levels without 
going for toxicity.  The P value is 0.0270 which is significant. 
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TABLE – 9 
MODE OF INDUCTION 
 
Group A  
(Dhaka 
Regimen) 
Group B  
(Pritchard 
Regimen) 
S. 
No. Mode of Induction 
No. % No. % 
1. Syntocinon 27  67.50 24  60 
2. Prostaglandin E2 gel 13  32.50 16  40 
 
 
 In Dhaka regimen group 27 patients were induced with syntocinon 
and 13 patients were induced with Prostaglandin E2 gel.   
 
 In Pritchard regimen group 24 patients were induced with 
syntocinon and 16 patients with Prostaglandin E2 gel.   
 
 
 
 
FIG. 8 
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TABLE – 10 
MATERNAL OUTCOME IN THE TWO GROUPS 
 
Group A 
(Dhaka Regimen) 
Group B 
(Pritchard 
Regimen) 
S. 
No. Mode of Delivery 
No. % No. % 
 Vaginal 26 65 27 67.5 
1. LN Delivery 22 55 20 50 
2. Outlet forceps 03 7.5 05 12.5 
3. Assisted Breech delivery 01 2.5 02 5.0 
 LSCS 14 35 13 32.5 
 P Value 0.816 (Not Significant) 
 
 
 Out of 40 patients in Dhaka regimen group 22 patients delivered by 
Labour Natural, 3 patients by outlet forceps and 1 patient by Assisted 
Breech delivery and 14 patients delivered by emergency LSCS. 
 Out of 40 patients in Pritchard regimen group 20 patients delivered 
by Labour Natural, 5 patients by outlet forceps and 2 patients by Assisted 
Breech delivery and 13 patients delivered by emergency LSCS. 
 The P value is 0.816, which is not significant. 
FIG. 9 
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TABLE – 11 
INDUCTION TO DELIVERY INTERVAL 
 
Group A  
(Dhaka Regimen) 
Group B  
(Pritchard Regimen) S. 
No. 
Induction to 
Delivery 
Interval 
No. % No. % 
1. Less than 6 hrs. 13 32.50 18 45.00 
2. 6.1 – 12 hrs. 27 67.50 21 52.50 
3. 12.1 – 18 hrs. 00 00.00 01 02.50 
 Mean 12.210 12.816 
4. Standard 
Deviation 
3.2852 3.821 
5. P Value 0.123 
 
 The Mean duration of Induction to delivery interval in Dhaka 
regimen group was 12.21 hours and in Pritchard regimen group it was 
12.82 hours. The P value is 0.123 which is not significant. 
FIG. 10 
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TABLE – 12 
TREATMENT COMPLICATIONS IN WOMEN RECEIVING  
MAGNESIUM SULPHATE FOR ECLAMPSIA 
 
Group A  
(Dhaka Regimen) 
Group B   
(Pritchard 
Regimen) 
S. 
No. Variables 
No. % No. % 
P 
1. Loss of knee jerk 
reflex 
02 5.0 05 12.50 0.02 
2. Oliguria 01 2.5 04 10.00 0.04 
3. Seizure recurrence 02 5.0 01 2.50 0.12 
4. Number of patients 
required dose deferral  
03 7.5 09 2.50 0.03 
 
 In Dhaka regimen group, 2 patients had loss of knee jerk reflex, 1 
patient had oliguria and 2 patients had seizure recurrence. In Pritchard 
regimen group, 5 patients had loss of knee jerk reflex, 4 patients had 
oliguria and 1 patient had seizure recurrence.   
 In Pritchard regimen group 9 patients required dose deferral which 
is significantly higher than the Dhaka regimen group, in which only 3 
patients required dose deferral due to loss of knee jerk reflex and oliguria. 
FIG. 11 
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TABLE – 13 
MATERNAL CONDITION AT DISCHARGE 
 
Group A Group B 
S. 
No. 
Condition of the 
Mother 
No. % No. % 
1. Alive 40 100 40 100 
2. Residual 
Sequelae 
00 00 00 00 
3. Dead 00 00 00 00 
 
In both the treatment groups, all mothers were alive at the time of 
discharge and none had residual sequlae and there was no maternal 
mortality in both the regimen groups. 
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TABLE – 14 
PERINATAL OUTCOME 
 
Group A 
(Dhaka regimen) 
Group B 
(Pritchard regimen) S. 
No. 
Condition of 
Child after 
Delivery 
No. % No. % 
1. Alive 18 45.00 20 50.00 
2. Still Born 13 32.50 09 22.50 
3. Neonatal death 09 22.50 11 27.50 
4. P Value 0.114 (Not Significant) 
 
 In the Dhaka regimen group, 18 babies were alive, 13 babies were 
still born and 9 neonatal deaths.  In the Pritchard regimen group 20 babies 
were alive, 9 babies were still born and 11 neonatal deaths.  The P value 
is 0.114 which is not significant. 
 
 FIG. 12 
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TABLE – 15 
BIRTH WEIGHT OF BABIES IN THE TWO GROUPS 
 
S. 
No. 
Birth weight of Babies 
(in Kg.) 
Group A Group B 
1. Less than 1 01 01 
2. 1 – 1.5 08 04 
3. 1.6 – 2.5 21 27 
4. More than 2.5 10 08 
5. Mean 1.9356 1.5000 
6. Standard Deviation 0.59562 0.50315 
7. P Value 0.051 
 
 The mean birth weight of the babies in Dhaka regimen group was  
1.94 ± 0.59 kg and in Pritchard regimen group the mean birth weight was 
1.5 ± 0.50 kg.  The P value being 0.051 which is not significant. 
FIG. 13 
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TABLE – 16 
COMPARISON OF PERINATAL DEATHS IN BOTH GROUPS  
 
Perinatal Deaths 
 Total Births 
No. % 
Group A 40 22 55 
Group B 40 20 50 
 
 There were 22 perinatal deaths in group A out of 40 births and 20 
perinatal deaths in group B out of 40 births. 
 
FIG. 14 
COMPARISON OF PERINATAL DEATHS IN BOTH GROUPS  
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DISCUSSION 
 
 Prevention of further seizures in eclampsia is associated with a 
reduction in adverse outcomes.  Magnesium is an ideal drug, with rapid 
onset of action, a non sedative effect on mother and baby, a fairly wide 
safety margin and a readily available antidote in the form of calcium 
gluconate.  The Collaborative Eclampsia Trial provided vital evidence 
that magnesium reduces the risk of recurrent seizures compared to other 
standard agents diazepam and phenytoin.  Further more use of 
magnesium sulphate does not appear to be associated with detrimental 
effects on the neonate. 
 Evidence from computed tomography and magnetic resonance 
angiographic studies implicating cerebral vasospasm and ischemia in the 
genesis of eclampsia.  Magnesium seems to reverse and ameliorate the 
effects of cerebral ischemia. There may also be a moderate inhibitory 
effects on cortical discharge with magnesium antagonizing the excitatory 
glutamate N-methyl aspartate receptor. 
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 Falling serum calcium levels following administration of intra 
venous magnesium sulphate inhibit acetyl choline release at motor end 
plate.   
 In this study, a total of 10 gms of MgSO4 as a loading does and 2.5 
gms of MgSO4 4th hourly as maintenance dose was used which was just 
over half the dose used by Pritchard regimen and in Collaborative 
Eclampsia Trial. 
 
Age Distribution 
 A study in N.W.M. Hospital, Bombay in 1989 reveals that 40.5% 
were under 20 years, 56.8% were between 21 – 29 and 2.7% above 30 
years.  Lolkand et al. in his study (1997) found that 40.7% were under 20 
years.  In a study by Katz et al. (2000) in the sacred heart medical center 
USA the mean age of eclampsia was 22 years. 
 In this study, the mean age in Dhaka regimen group was 24.16 
years and the mean age in Pritchard regimen group was 24.38 years. 
 
Parity 
 In the study of Collaborative Eclampsia Trial Group (1995) 64% 
were primis.  In the study by N.W.M. Hospital, Bombay (1989) 64.9% 
were primis.  According to Mudhaliar over 75% were primis.  In the 
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present study, in Dhaka regimen group 67.5% were primis and in 
Pritchard regimen group 60% were primis. 
 
Gestational Age 
 In Collaborative Eclampsia Trial Group study (1995) 39.5% cases 
were less than 34 weeks and 25.5% cases were presented between 34 – 36 
weeks and 33% cases were presented at term.  In the present study mean 
gestational age in Dhaka regimen group was 32.93 weeks and in Pritchard 
regimen group it was 33.39 weeks. 
 
Diastolic Blood Pressure 
 In Collaborative Eclampsia Trial Group study (1995) 53% had a 
diastolic blood pressure above or equal to 110 mm Hg.  In the present 
study majority of patients had diastolic blood pressure between 100 – 110 
mm Hg and in Dhaka regimen group it was 45% and in Pritchard regimen 
group it was 33%. 
 
Recurrence rate of convulsions 
 The recurrence rate of convulsions after starting the regimen in 
Dommisse (1990) was  0%, in Collaborative Eclampsia Trial Group study 
(1995) was 5.7%, in PGI Chandigarh, it was 8.1%.  In the present study, 
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5% of patients had recurrent convulsions in Dhaka regimen group and 
2.5% of patients had recurrent convulsions in Pritchard regimen group. 
 
Mode of induction 
 Alexander and colleagues (1999) reviewed 278 singleton liveborn 
infants weighing 750 – 1500 gm delivered by women with severe pre 
eclampsia in Parkland hospital.  50% were induced and 50% underwent 
caesarean delivery without labor.  Induction was not successful in 35% of 
women in  induced group.  Similar results were reported by Nassar et al. 
(1918). 
 In the present study, in Dhaka regimen group 32.5% of patients 
were induced with syntocinon and 67.5% were induced with 
prostaglandin E2 gel.  Among them, 65% delivered vaginally and 35% 
underwent caesarean section. 
 In Pritchard regimen group, 60% were induced with syntocinon 
and 40% with prostaglandin E2 gel.  Among them, 67.5% delivered 
vaginally and 32.5% by caesarean section. 
 
Perinatal Mortality 
 Perinatal deaths in Collaborative Eclampsia Trial Group (1995) 
with magnesium sulphate was 25%, with Diazepam it was 22% and with 
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Phenytoin it was 31%.  In the present study, in Dhaka regimen group the 
total number of perinatal death was 22 and in Pritchard regimen group it 
was 20. 
Maternal Morbidity and Mortality 
 The maternal mortality between 1991 – 1997 was approximately 
6% in US were related to eclampsia.  (Berg & Coworkers, 2003).  The 
maternal mortality in Collaborative Eclampsia Trial Group 1995 with 
magnesium sulphate was 3.8%.  In the present study, in both the Dhaka 
regimen and Pritchard regimen groups no maternal death occurred. 
 2 patients developed loss of knee jerk reflex with low dose Dhaka 
regimen group and 5 patients developed loss of knee jerk reflex in the 
Pritchard regimen group. In Pritchard regimen group 9 patients required 
dose deferral which is significantly higher than the Dhaka regimen group, 
in which only 3 patients required dose deferral due to loss of knee jerk 
reflex and oliguria. The mean serum magnesium level in Dhaka regimen 
was 4.03 mg/dl and in Pritchard regimen group it was 4.53 mg/dl.  Both 
the values lie within the therapeutic serum magnesium level. 
 
 
 
 
SUMMARY 
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SUMMARY 
 
Variables 
Dhaka regimen 
(Group A – 40) 
Pritchard regimen  
(Group B – 40) 
Recurrence of fits   
No. of cases 2 1 
(%) 5% 2.5% 
Mean Serum 
Magnesium Level 
4.03 mg/dl 4.53 mg/dl 
Mode of Delivery   
Vaginal 26 27 
LSCS 14 13 
Perinatal Outcome   
Live Born 18 20 
Still Born 13 9 
Neonatal death 9 11 
Total Perinatal Deaths 22 20 
 
§ In the present study, 40 Antepartum eclamptic patients were treated 
with lower dose Dhaka regimen and 40 Antepartum eclamptic 
patients were treated with Pritchard regimen of magnesium 
sulphate and the two groups were compared with respect to the 
safety and efficacy of treatment, complications, serum magnesium 
level, maternal and perinatal outcome. 
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§ Recurrence of fits after starting the regimen was lower in both the 
magnesium sulphate regimen groups. 
§ Only 1 patient (2.5%) in the Pritchard regimen group had 
recurrence of fits and 2 patients (5%) had recurrence of fits in the 
Dhaka regimen group who were managed with an additional dose 
of 2 gm of intra venous MgSO4. 
§ The mean serum magnesium level in Dhaka regimen group was 
4.03 mg/dl and in Pritchard regimen group it was 4.53 mg/dl. 
§ 65% of patients delivered vaginally in Dhaka regimen group and 
67.5% of patients delivered vaginally in Pritchard regimen group. 
§ LSCS was done for obstetric indications and for medical 
indications. 
§ 18 babies were alive in the Dhaka regimen group and 20 babies 
were alive in the Pritchard regimen group. 
§ The perinatal death in Dhaka regimen group was 22 (55%) and in 
Pritchard regimen group it was 20 (50%). 
§ There was no maternal mortality in both the groups and all mothers 
were discharged in good condition with no residual sequlae. 
§ The perinatal outcome does not differ significantly in both the 
groups. 
 
 
 
 
CONCLUSION 
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CONCLUSION 
 
 Magnesium sulphate is the anti convulsant drug of choice in 
women with eclampsia. The low dose Dhaka regimen used for smaller 
women appears to control and prevent convulsions effectively. In the 
present study of Dhaka regimen, the serum magnesium levels remain 
below the toxic levels. 
 The present study provides further strong support for the routine 
use of magnesium sulphate for eclamptic convulsions.  As long as there 
is adequate urinary output, clinical monitoring appears to be sufficient. 
 There is no difference in maternal mortality, perinatal mortality, 
maternal morbidity and cesarean section rates among the both magnesium 
sulphate regimen groups. 
 The induction delivery interval between the two groups does not 
differ significantly. The study clearly shows that Dhaka regimen is almost 
equivalent to Pritchard regimen, for the control of convulsions in 
eclampsia. 
 Proper antenatal care, improved socio economic status and 
intensive management will largely reduce the incidence of eclampsia 
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which is an important cause of maternal morbidity and mortality, 
perinatal morbidity and mortality. 
 In conclusion, seizures can be safely controlled in women with 
eclampsia with a lower dose of magnesium sulphate, with the advantage 
of a lower magnesium toxicity. 
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PROFORMA 
 
NAME  :    AGE : 
ADDRESS  :    IPNO :  
OCCUPATION : 
SOCIO ECONOMIC STATUS  : 
DATE & TIME OF ADMISSION : 
DATE & TIME OF DELIVERY : 
DATE OF DISCHARGE   : 
OBSTETRIC CODE   : 
LMP      : 
EDD      : 
GA      : 
BOOKED / UNBOOKED   : 
HISTORY OF PRESENTING ILLNESS: 
Brought – Conscious /semiconscious/ Coma : 
No. of convulsions before admission : 
          during admission : 
Headache / Vomiting / Blurring of vision / Epigastric pain / Oliguria / 
Pedal edema / Fever / fits 
Labour pain / Bleeding PV / Draining PV  
MENSTRUAL H/O 
MARITAL H/O 
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OBSTETRIC H/O 
Previous Obstetric Outcome 
PAST H/O  - HT / Epilepsy / Jaundice / DM / PIH /Eclampsia 
    in previous pregnancy 
PERSONAL H/O - Smoker / Non-smoker 
FAMILY H/O - HT / Epilepsy / DM / Twins / Others  
 
GENERAL EXAMINATION 
 Consciousness 
 Orientation 
 Pallor 
 Oedema – site and grading 
 Cyanosis 
 
VITALS   Temp   PR  BP  RR 
SYSTEMIC EXAMINATION 
  CVS 
  RS 
  CNS  
DTR – Absent / Normal / Exaggerated 
 
ABDOMEN 
 P / A    EFW : 
 P / V     Bishop Score : 
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STATUS OF PREGNANCY 
 Single / Multiple / Molar 
 
PERIOD OF GESTATION 
 Term > 37 wks / Preterm 20-36 wks / < 20 wks 
IN LABOUR  - Yes / No – Duration 
PLAN OF MODE OF DELIVERY 
 Induction / Accelaration 
 Vaginal / LSCS : Indication for LSCS 
 
INVESTIGATION 
 URINE  - Sugar / Albumin / Microscopy – Puscells, Casts  
 24 Hrs Urine protein / creatinine clearance  
 Complete Hemogram  
 Platelet count 
 BT 
 CT 
 CRT 
 Plasma Fibrinogen 
 Blood sugar 
 Blood Urea  
 Serum Creatinine 
 Serum Uric acid 
 Serum Electrolytes 
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 Liver function test 
 Serum Magnesium 
 Peripheral smear study 
 USG 
Fundus examination  
 
MATERNAL OUTCOME 
 Mode of delivery – Vaginal / Instrumental / LSCS  Time of 
delivery 
MgSo4 Regimen given  
No. of recurrent convulsions after receiving MgSo4 
Did the mother show signs of toxicity  
Maternal complications during hospital stay 
Condition of the mother at discharge – Healthy / Residual Sequlae / 
 died 
FETAL OUTCOME 
 Still born / Alive    -  Sex 
 Apgar score    -  1min   & 5 mins 
 Weight    -   Kg 
 Congenital abnormality if any  - 
 Condition of child at discharge -  Healthy / Residual sequlae / 
       died  
 Cause of Neonatal death 
 
 
 
 
MASTER CHART 
 
 
 
 
BP (mm Hg) Maternal Outcome Perinatal Outcome 
S. 
No. Name Age IP No. 
OBST 
Code 
Book 
Status 
GA in 
WKS 
No. of 
fits BEF 
ADM 
Level of 
Conscious 
Syst. Dias 
Reg. 
Group 
S. Mg 
mg/dl MOI MOD 
Adm. 
Del. 
Int. 
(Hrs.) 
Seizure 
recurrence 
Signs 
of 
MgSO4 
toxicity 
Dose 
deferral 
Condition 
at 
discharge 
Bwt Condition 
1. Akilandam 26 23212 G2P1L1 2 34 4 2 170 110 A 4.2 0 2 0.5 - - - 1 2.1 1 
2. Mayil 22 24228 G2P1L1 1 32 3 2 160 100 A 4 3 1 6 - - - 1 1.8 2 
3. Juliet Regina 35 24301 G4P3L3 2 30 1 2 160 120 B 4.6 3 1 7 - + 3 1 1.2 2 
4. Sathya Priya 24 25363 Primi 1 36 2 2 180 110 A 3.8 1 2 2.4 - - - 1 2.5 1 
5. Rathna 25 25488 Primi 1 32 2 1 170 110 B 5.2 3 1 5 - - - 1 2.1 1 
6. Pappathi 29 26040 G2P1L1 2 34 3 2 160 110 B 5 1 1 6.2 - - - 1 2.2 1 
7. Semmina 24 27151 Primi 2 28 7 2 150 100 A 3.2 1 1 8 - - - 1 0.9 2 
8. Karpagam 37 27426 Primi 1 36 5 2 140 110 B 4.8 1 2 8 - + 1 1 2.7 1 
9. Mala 32 27575 Primi 2 38 3 2 180 120 B 3 3 2 1.5 + - - 1 2.7 1 
10. Fairose 27 28279 G3P2L1 2 36 2 2 190 110 A 4.4 3 1 3 - - - 1 2 3 
11. Muthulaxmi 25 29672 G2P1L0 1 32 4 2 160 100 A 4 1 1 8 - - - 1 1.9 3 
12. Rebamaxy 31 30350 G3P2L2 1 34 3 2 150 110 A 3.7 3 1 4.5 - - - 1 2.1 1 
13. Palaniammal 20 30495 Primi 2 32 1 1 140 90 B 4.6 1 1 8.4 - - - 1 1.8 1 
14. Sathya 23 30632 G2P1L1 2 36 3 2 160 100 B 4.7 3 2 7.3 - - - 1 2 1 
15. Uma 24 31562 G3P2L2 2 34 2 2 160 110 B 5.2 3 1 4 - - - 1 2 3 
16. Parasakthi 29 32985 G2P1L1 2 24 3 2 150 110 A 4 1 1 11 - - - 1 0.8 2 
17. Sangeetha 19 34196 Primi 1 28 2 1 150 90 A 4.2 1 1 9 - - - 1 1 2 
18. Revathi 20 34906 Primi 2 36 3 2 140 100 B 4.8 3 1 6 - - - 1 2.7 1 
19. Iyyammal 21 36519 Primi 1 38 4 1 130 90 B 5.4 1 2 9 - - - 1 2.6 1 
20. Maheswari 20 36934 Primi 1 36 6 2 160 110 A 4.8 1 2 8 - - - 1 2.5 1 
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BP (mm Hg) Maternal Outcome Perinatal Outcome 
S. 
No. Name Age IP No. 
OBST 
Code 
Book 
Status 
GA in 
WKS 
No. of 
fits BEF 
ADM 
Level of 
Conscious 
Syst. Dias 
Reg. 
Group 
S. Mg 
mg/dl MOI MOD 
Adm. 
Del. 
Int. 
(Hrs.) 
Seizure 
recurrence 
Signs 
of 
MgSO4 
toxicity 
Dose 
deferral 
Condition 
at 
discharge 
Bwt Condition 
21. Sumathi 27 38770 G3P2L1 1 32 5 2 170 120 B 5.3 3 1 4 - - - 1 2.2 3 
22. Selvarani 25 39464 G2P1L1 2 34 4 1 150 100 A 5.2 3 2 6 - - - 1 2 3 
23. Manjula 25 40993 Primi 2 34 3 2 150 110 B 5.8 1 1 8 - - - 1 1.8 2 
24. Padma 19 42098 Primi 1 30 2 1 140 90 A 4 1 1 11 - - - 1 1.2 2 
25. Lalitha 26 42797 Primi 1 36 2 2 180 110 B 4.8 1 2 7 - + + 1 1.9 1 
26. Lakshmi 20 44163 Primi 1 32 8 2 170 110 A 4.2 1 1 8 - - - 1 1.5 2 
27. Hairunisa 21 46058 Primi 1 34 3 2 160 120 A 3.8 3 1 5 - - - 1 1.5 3 
28. Kokila 24 49630 G2P1L1 1 38 1 1 190 100 A 4 1 2 10 - - - 1 2.9 1 
29. Sellarani 22 49942 G2P1L0 1 38 4 2 180 100 A 4 1 2 10 - - - 1 2.9 1 
30. Kalaiselvi 21 50442 Primi 1 30 1 1 130 100 B 4.6 1 1 7.5 - - - 1 1.7 3 
31. Tamilselvi 20 57376 Primi 1 34 3 2 160 110 B 5 1 1 0.3 - - - 7 2.1 1 
32. Pappathi 27 51548 G2P1L1 2 32 1 1 170 110 A 4.2 1 1 4 - - - 1 1.8 3 
33. Poomani 21 51872 Primi 1 36 4 2 180 120 B 4.8 1 2 0.5 - - - 1 2.2 1 
34. Thilagavathi 22 52004 Primi 2 34 2 1 150 100 A 3.6 1 1 6 - - - 1 2 1 
35. Lalitha 25 53134 G3P2L2 1 36 5 2 170 120 B 5.4 3 2 7 - - - 1 2.5 1 
36. Rajeswari 19 53868 Primi 1 30 3 2 160 100 A 4.4 1 1 10 - - - 1 1.7 2 
37. Rahmath 20 54551 Primi 1 36 2 2 170 110 A 4.6 3 1 1.2 - - - 1 2.3 1 
38. Banupriya 24 55410 Primi 1 38 6 2 160 100 B 6 3 2 2.5 - + + 1 2.6 1 
39. Vellammal 30 57986 G3P2L2 1 34 5 1 190 120 B 5.8 3 1 1 - - - 1 3 1 
40. Aruldevi 27 1794 G2P1L1 2 34 6 2 170 110 A 4.8 1 1 6 - + + 1 2.4 3 
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BP (mm Hg) Maternal Outcome Perinatal Outcome 
S. 
No. Name Age IP No. 
OBST 
Code 
Book 
Status 
GA in 
WKS 
No. of 
fits BEF 
ADM 
Level of 
Conscious 
Syst. Dias 
Reg. 
Group 
S. Mg 
mg/dl MOI MOD 
Adm. 
Del. 
Int. 
(Hrs.) 
Seizure 
recurrence 
Signs 
of 
MgSO4 
toxicity 
Dose 
deferral 
Condition 
at 
discharge 
Bwt Condition 
41. Sathya 23 1892 Primi 2 32 3 2 160 90 B 5.6 1 1 13 - + + 1 2 3 
42. Suguna 26 2126 Primi 1 30 2 2 130 100 B 5.2 3 1 2.5 - - - 1 1.6 3 
43. Thangam 20 1577 Primi 1 36 4 2 160 110 A 3.8 3 2 2 - - - 1 2.4 1 
44. Lakshmi 22 2588 Primi 2 28 2 2 150 100 A 3.6 1 1 12 - - - 1 1 2 
45. Kasambu 25 4207 G2P1L1 2 34 1 1 200 120 B 4.8 3 2 3 - - - 1 2 3 
46. Usha 23 8330 Primi 1 36 6 2 170 110 B 4.4 1 1 10 - - - 1 2.4 1 
47. Valarmathi 25 9502 Primi 1 34 3 2 140 100 A 4.2 3 1 6 - - - 1 2.1 3 
48. Amudha 28 10310 G4P3L2 2 33 2 2 190 120 A 4.6 3 1 2 - + + 1 2 2 
49. Lakshmi 27 13512 Primi 2 28 2 2 180 110 A 4 1 2 1.5 - - - 1 0.9 2 
50. Rathnammal 25 14436 Primi 1 24 4 2 170 120 A 4.4 1 1 10 - - - 1 0.7 2 
51. Parimala 24 15069 Primi 1 32 3 2 160 110 B 4.2 1 1 9 - - - 1 1.6 2 
52. Nirmala 27 15512 Primi 2 34 1 1 180 120 B 4.6 1 1 7 - + + 1 1.8 3 
53. Revathi 21 15642 Primi 1 38 3 2 190 120 B 4.8 1 2 2.5 - - - 1 3 1 
54. Chellathaye 22 16372 Primi 1 32 2 1 170 120 A 4.2 1 2 7 + - - 1 2 3 
55. Rajeshwari 19 16763 Primi 1 34 3 2 150 110 A 3.8 1 1 10 - - - 1 2.1 1 
56. Maha 25 18185 G4P3L3 2 28 5 2 160 120 B 5.2 3 1 4 - - - 1 1.5 2 
57. Parameshwari 25 15388 Primi 1 26 1 1 180 100 A 4 1 1 11 - - - 1 0.8 2 
58. Vanitha 22 20376 Primi 2 32 1 2 190 120 A 3.6 1 2 8 - - - 1 1.6 2 
59. Kalaiselvi 35 21636 G5P2L2A2 2 32 3 2 190 130 B 5 1 1 7 - - - 1 1.5 2 
60. Radhika 30 22733 Primi 1 26 2 7 200 110 B 5.2 1 1 12 - - - 1 0.6 2 
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BP (mm Hg) Maternal Outcome Perinatal Outcome 
S. 
No. Name Age IP No. 
OBST 
Code 
Book 
Status 
GA in 
WKS 
No. of 
fits BEF 
ADM 
Level of 
Conscious 
Syst. Dias 
Reg. 
Group 
S. Mg 
mg/dl MOI MOD 
Adm. 
Del. 
Int. 
(Hrs.) 
Seizure 
recurrence 
Signs 
of 
MgSO4 
toxicity 
Dose 
deferral 
Condition 
at 
discharge 
Bwt Condition 
61. Suganya 20 24121 Primi 2 30 2 2 160 100 B 5 1 1 5 - - - 1 1.5 2 
62. Selvamani 19 27951 Primi 1 26 4 2 150 120 A 4.2 1 1 11 - + + 1 0.75 2 
63. Vijaya 27 29525 Primi 1 28 1 2 160 110 A 4.4 1 1 10.2 - - - 1 1 2 
64. Neelavathi 20 31470 Primi 1 32 3 2 170 110 B 4.8 1 1 8 - - - 1 2 1 
65. Priya 18 31583 G2A1 2 34 3 2 180 100 B 5.2 1 2 3.4 - - - 1 2.3 1 
66. Vijayarani 20 31699 Primi 1 36 2 1 170 110 A 4.4 3 2 2.1 - - - 1 2.8 1 
67. Akila 27 32133 G2P1L1 1 34 8 2 160 120 B 5 1 1 8 - + + 1 2 3 
68. Manjula 25 32393 Primi 1 32 3 2 150 100 B 4.8 1 1 9 - - - 1 1.9 3 
69. Saradha 25 33157 G4P3L1 1 34 4 2 170 120 A 4.2 3 1 4 - - - 1 1.5 2 
70. Selvi 35 35255 G2P1L1 2 32 4 2 170 100 B 5.2 3 1 5 - - - 1 1.6 2 
71. Annakamu 24 36210 Primi 1 28 7 2 170 110 A 4 1 1 11 - - - 1 1.25 2 
72. Sangeetha 27 37262 G2P1L0 1 36 4 2 180 120 B 4.8 3 2 3.5 - - - 1 2 3 
73. Revathi 20 37290 Primi 1 30 1 2 180 130 A 3.6 1 1 10 - - - 1 2 3 
74. Rosemary 20 37321 Primi 1 34 4 2 160 120 A 3.4 1 2 7.3 - - - 1 2.1 1 
75. Veerayee 19 38100 Primi 1 36 2 1 170 110 A 3.2 3 2 0.5 - - - 1 2.7 1 
76. Noorjahan 23 39206 G3P2L2 1 38 5 2 150 190 B 5.4 3 1 3 - + + 1 3.1 1 
77. Muthukani 20 39329 G2P1L1 2 36 3 2 190 110 B 5.2 1 2 6.3 - - - 1 2.3 1 
78. Kavitha 24 39411 Primi 1 32 4 2 160 110 B 5.6 1 1 9 - + + 1 1.8 2 
79. Sarasu 22 39452 G2P1L1 1 34 2 1 170 100 B 5 1 1 3.3 - - - 1 2.1 3 
80. Kamatchi 26 39591 Primi 1 36 3 2 170 120 A 4.2 1 2 8 - - - 1 2.75 1 
ABBREVIATIONS 
OBST CODE  - Obstetric Code 
BOOK STATUS  - Booking Status 
 1   - Booked 
 2   - Unbooked 
GA    - Gestational Age in weeks 
No. of fits BEF ADM - Number of fits before Admission 
Level of Conscious 
 1   - Conscious 
 2   - Semiconscious 
BP    - Blood Pressure 
Syst.    - Systolic 
Dias.    - Diastolic 
Reg. Group   - Regimen Group 
A   - Dhaka regimen 
B   - Pritchard regimen 
S. Mg    - Serum Magnesium 
MOI    - Mode of Induction 
 0   - No induction 
 1   - Prostaglandin E2 gel 
 2   -  Oxytocin 
MOD    - Mode of Delivery 
 1   - Vaginal Delivery 
 2   - LSCS 
ADI    - Admission to Delivery Interval (in hours) 
Condition of Mother at Discharge 
 1   - Alive 
 2   - Residual Sequlae 
 3   - Dead 
Condition of the baby at Discharge 
 1   - Alive 
 2   - Still born 
 3   - Neonatal death 
